DJ receives funding from the National Institutes of Health and the Minnesota Partnership for Biotechnology and Genomics. Funding Information: Conflict of Interest Statement: JG-R and KJ receive funding from the National Institutes of Health. Note = "Funding Information: The authors wish to thank the staff from the Department of Neurology at the Mayo Clinic in Rochester, Minnesota for clinical and administrative support. FDG-PET may also complement MRI in distinguishing TEA from neurodegenerative disease when suspected.", In the appropriate clinical context, our findings support the use of early prolonged EEG with emphasis on sleep monitoring as a key diagnostic tool. This syndrome is frequently associated with persistent interictal cognitive/behavioral symptoms and thus can be mistaken for common mimics. Conclusions: TEA is a treatable cause of amnestic spells in older adults. Anti-seizure therapy, most often with a single agent, resulted in improvement (reduction in spell frequency and/or subjective improvement in interictal cognitive/behavioral complaints) in all 17 cases with available follow-up. FDG-PET identified focal hypometabolism in 2/8 cases where it was performed, both involving the frontal and/or temporal regions. Brain MRI revealed focal abnormalities in only 4/19 cases (21%). In numerous cases, sleep and prolonged EEG evaluations identified abnormalities not previously seen on shorter or awake-state studies. EEG revealed epileptiform abnormalities involving the frontal and/or temporal regions in 12/19 individuals (63%), including activation during sleep in all of these cases. Thirteen patients (68%) reported persistent cognitive/behavioral symptoms, including 4 (21%) for whom these were the chief presenting complaints. Results: Nineteen patients were identified (14 men, 5 women) with median onset age 66 years and median time to diagnosis 2 years. Diagnostic criteria included the presence of recurrent episodes of transient amnesia with preservation of other cognitive functions and evidence for epilepsy. Methods: We performed a retrospective analysis of patients diagnosed with TEA at the Mayo Clinic Minnesota from Januto September 21, 2017. FDG-PET may also complement MRI in distinguishing TEA from neurodegenerative disease when suspected.Ībstract = "Objective: To characterize the clinical, EEG, and neuroimaging profiles of transient epileptic amnesia (TEA). Objective: To characterize the clinical, EEG, and neuroimaging profiles of transient epileptic amnesia (TEA).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |